JHX vs NEM

JHX presents a stark contrast between deterministic value and growth expectations, with a Piotroski F-Score of 4/9 indicating stable but mediocre financial health and a Graham Number of $7.72 suggesting the stock is significantly overvalued. While revenue growth is robust at 30.10%, earnings have collapsed by 64.10% YoY, leading to an unsustainable trailing P/E of 90.79. The market is currently pricing in a massive recovery, as evidenced by the Forward P/E of 17.45 and a PEG ratio of 0.97. Despite strong analyst buy recommendations, the technical trend is bearish and the intrinsic value is severely disconnected from the current price.

Newmont Corporation presents a dichotomy between strong operational fundamentals and significant valuation premiums. While the Piotroski F-Score of 4/9 indicates stable health and the balance sheet is pristine with a Debt/Equity ratio of 0.17, the stock trades at a substantial premium to its Graham Number ($66.88) and Intrinsic Value ($44.73). Recent quarterly earnings beats are impressive, yet bearish insider sentiment and a 0/100 technical trend suggest a lack of immediate conviction from internal stakeholders and market momentum. The overall outlook is neutral as strong profitability is offset by overvaluation and negative insider signals.